MINJUVI 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
PSUSA/10951
Periodic Safety Update EU Single assessment - 
31/08/2023 
n/a 
PRAC Recommendation - maintenance 
/202301 
tafasitamab 
R/0009 
Renewal of the marketing authorisation. 
25/05/2023 
24/07/2023 
The CHMP, having reviewed the available information on 
the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
II/0008 
Update of section 4.4 of the SmPC in order to add a 
12/05/2023 
24/07/2023 
SmPC, Annex 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Minjuvi, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
Not applicable 
II and PL 
For more information, please refer to the Summary of 
Product Characteristics. 
new warning on Progressive Multifocal 
Leukoencephalopathy (PML) based on post-
marketing data; the Package Leaflet is updated 
accordingly. The RMP version 2.0 has also been 
submitted. In addition, the MAH took the opportunity 
to implement editorial changes in the SmPC and to 
bring the PI in line with the latest QRD template 
version 10.3. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IB/0010 
B.II.h.1.b.2 - Update to the Adventitious Agents 
25/04/2023 
n/a 
Safety Evaluation information - Replacement of 
obsolete studies related to manufacturing steps and 
adventitious agents already reported in the dossier - 
without modifications of risk assessment 
PSUSA/10951
Periodic Safety Update EU Single assessment - 
16/03/2023 
n/a 
PRAC Recommendation - maintenance 
/202207 
tafasitamab 
IB/0006/G 
This was an application for a group of variations. 
12/10/2022 
n/a 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.d.1.z - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
PSUSA/10951
Periodic Safety Update EU Single assessment - 
01/09/2022 
n/a 
PRAC Recommendation - maintenance 
/202201 
tafasitamab 
R/0003 
Renewal of the marketing authorisation. 
19/05/2022 
08/07/2022 
The CHMP, having reviewed the available information on 
IA/0004 
A.6 - Administrative change - Change in ATC 
30/03/2022 
08/07/2022 
SmPC 
Code/ATC Vet Code 
the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for MINJUVI, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0002 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
05/01/2022 
08/07/2022 
SmPC, Annex 
life of the finished product - Biological/immunological 
II and PL 
medicinal product in accordance with an approved 
stability protocol 
IAIN/0001 
B.II.b.2.c.1 - Change to importer, batch release 
15/09/2021 
08/07/2022 
SmPC, Annex 
arrangements and quality control testing of the FP - 
II and PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
